
CLAIMS

1. A compound of formula (I),



(I)

a *N*-oxide form, an addition salt or a stereochemically isomeric form thereof, wherein

m is 0, 1, or 2 and when m is 0 then a direct bond is intended;

n is 0, 1, 2, or 3 and when n is 0 then a direct bond is intended;

p is 0, or 1 and when p is 0 then a direct bond is intended;

s is 0, or 1 and when s is 0 then a direct bond is intended;

t is 0 or 1 and when t is 0 then a direct bond is intended;

X is C(=O) or CHR^8; wherein

R^8 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -C(=O)-$NR^{17}R^{18}$, hydroxycarbonyl, arylC_{1-6}alkyloxycarbonyl, heteroaryl, heteroarylcarbonyl, heteroarylC_{1-6}alkyloxycarbonyl, piperazinylcarbonyl, pyrrolidinyl, piperidinylcarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; piperazinylcarbonyl substituted with hydroxy, hydroxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl; pyrrolidinyl substituted with hydroxyC_{1-6}alkyl; or piperidinylcarbonyl substituted with one or two substituents selected from hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyl(dihydroxy)C_{1-6}alkyl or C_{1-6}alkyloxy(hydroxy)C_{1-6}alkyl;

R^{17} and R^{18} are each independently selected from hydrogen, C_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, arylC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl(C_{1-6}alkyl) or hydroxyC_{1-6}alkyl(arylC_{1-6}alkyl);


is -CR^9=C< and then the dotted line is a bond, -C(=O)-CH<, -CHR^9-CH< or -CHR^9-N<; wherein
each R^9 is independently hydrogen or C_{1-6}alkyl;

R^1 is hydrogen, aryl, heteroaryl, C_{1-6}alkyloxycarbonyl, C_{1-12}alkyl, or C_{1-12}alkyl substituted with one or two substituents independently selected from hydroxy, aryl, heteroaryl, amino, C_{1-6}alkyloxy, mono- or di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C_{1-6}alkylpiperazinyl, arylC_{1-6}alkylpiperazinyl, heteroarylC_{1-6}alkylpiperazinyl, C_{3-7}cycloalkylpiperazinyl and C_{3-7}cycloalkylC_{1-6}alkylpiperazinyl;

R^2 is hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyloxy, heteroarylC_{1-6}alkyloxy, phenylthio, hydroxyC_{1-6}alkylcarbonyl, C_{1-6}alkyl substituted with a substituent selected from amino, aryl and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from amino, aryl and heteroaryl;


R^3 is hydrogen, C_{1-6}alkyl, heteroaryl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl;


R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, hydroxy, amino or C_{1-6}alkyloxy; or
R^4 and R^5 together can optionally form a bivalent radical selected from methylenedioxy or ethylenedioxy;


R^6 is hydrogen, C_{1-6}alkyloxycarbonyl or C_{1-6}alkyl;


when p is 1 then R^7 is hydrogen, arylC_{1-6}alkyl, hydroxy or heteroarylC_{1-6}alkyl;


Z is a radical selected from



(a-1)



(a-2)



(a-3)



(a-4)



(a-5)



(a-6)


(a-7)


(a-8)


(a-9)


(a-10)


(a-11)

wherein

each R^{10} or R^{11} are each independently selected from hydrogen, halo, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, heteroaryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, heteroarylcarbonyl, C_{1-6}alkylcarbonyl, arylC_{1-6}alkylcarbonyl, heteroarylC_{1-6}alkylcarbonyl, C_{1-6}alkyloxy, C_{3-7}cycloalkylcarbonyl, C_{3-7}cycloalkyl(hydroxy)C_{1-6}alkyl, arylC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkenyl C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and $-(CH_2)_v-(C(=O)_r)-(CHR^{19})_u-NR^{13}R^{14}$; wherein

v is 0, 1, 2, 3, 4, 5, or 6 and when v is 0 then a direct bond is intended;

r is 0, or 1 and when r is 0 then a direct bond is intended;

u is 0, 1, 2, 3, 4, 5, or 6 and when u is 0 then a direct bond is intended;

R^{19} is hydrogen or C_{1-6}alkyl;

R^{12} is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, C_{1-6}alkyloxy and aryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and C_{1-6}alkyloxy;

R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, arylC_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylcarbonyl, $-(CH_2)_k-NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyloxy, aryl or heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, amino, arylC_{1-6}alkyl, heteroaryl or heteroarylC_{1-6}alkyl; or

R^{13} and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, or piperazinyl substituted with a substituent selected from C_{1-6}alkyl, arylC_{1-6}alkyl, arylC_{1-6}alkyloxycarbonyl, heteroarylC_{1-6}alkyl, C_{3-7}cycloalkyl and C_{3-7}cycloalkylC_{1-6}alkyl, wherein

k is 0, 1, 2, 3, 4, 5, or 6 and when k is 0 then a direct bond is intended;

R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl, arylC_{1-6}alkyloxycarbonyl, C_{3-7}cycloalkyl, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; and C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl, and heteroarylC_{1-6}alkyl; or

R^{15} and R^{16} together with the nitrogen to which they are attached can optionally form a morpholinyl, a piperazinyl or a piperazinyl substituted with C_{1-6}alkyloxycarbonyl;

aryl is phenyl or naphthalenyl;

each phenyl or naphthalenyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl and C_{1-6}alkyloxy; and

each phenyl or naphthalenyl can optionally be substituted with a bivalent radical selected from methylenedioxy and ethylenedioxy;

heteroaryl is pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl or tetrahydrofuranyl;

each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl, aryl, arylC_{1-6}alkyl or C_{1-6}alkyloxy; and

each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from *methylenedioxy or ethylenedioxy*;

with the proviso that

when m is 1; the substituents on the phenyl ring other than R^2 are in the meta position; s is 0; and t is 0; then

Z is a radical selected from (a-1), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8) or (a-9).

2. A compond according to claim 1 wherein $-Q^{\cdots\cdots}Y<$ is $-CR^9=C<$ and then the dotted line is a bond, $-CHR^9-CH<$ or $-CHR^9-N<$.

3. A compound according to claim 1 or 2 wherein X is C(=O) or CHR^8 wherein R^8 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, hydroxycarbonyl, arylC_{1-6}alkyloxycarbonyl, heteroarylC_{1-6}alkyloxycarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; R^1 is hydrogen, aryl, heteroaryl, C_{1-12}alkyl, or C_{1-12}alkyl substituted with one or two substituents independently selected from hydroxy, aryl, heteroaryl, amino, C_{1-6}alkyloxy, mono- or di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C_{1-6}alkylpiperazinyl, arylC_{1-6}alkylpiperazinyl, heteroarylC_{1-6}alkylpiperazinyl, C_{3-7}cycloalkylpiperazinyl and C_{3-7}cycloalkylC_{1-6}alkylpiperazinyl; R^3 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, polyhaloC_{1-6}alkyl, hydroxy, amino or C_{1-6}alkyloxy; R^4 and R^5 together can optionally form a bivalent radical selected from methylenedioxy or ethylenedioxy; R^6 is hydrogen or C_{1-6}alkyl; when p is 1 then R^7 is hydrogen, arylC_{1-6}alkyl or heteroarylC_{1-6}alkyl; Z is a radical selected from (a-1), (a-2), (a-3), (a-4), (a-5) and (a-6); each R^{10} or R^{11} are each

independently selected from hydrogen, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, heteroaryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, heteroarylcarbonyl, arylC_{1-6}alkylcarbonyl, heteroarylC_{1-6}alkylcarbonyl, C_{1-6}alkyloxy, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and $-(CH_2)_v-(C(=O)_r)-(CH_2)_u-NR^{13}R^{14}$; R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl, C_{3-7}cycloalkyl, $-(CH_2)_k-NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl and heteroarylC_{1-6}alkyl; R^{13} and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, or piperazinyl substituted with a substituent selected from C_{1-6}alkyl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, C_{3-7}cycloalkyl, and C_{3-7}cycloalkylC_{1-6}alkyl; R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; and C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl and heteroarylC_{1-6}alkyl; heteroaryl is pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl; and each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl and C_{1-6}alkyloxy, or each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from methylenedioxy or ethylenedioxy.

4. A compound according to claim 1 or 2 wherein;
R^8 is hydrogen, $-C(=O)-NR^{17}R^{18}$, arylC_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with hydroxy, piperazinylcarbonyl substituted with hydroxy, hydroxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, pyrrolidinyl substituted with hydroxyC_{1-6}alkyl or piperidinylcarbonyl substituted with one or two substituents selected from hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyl(dihydroxy)C_{1-6}alkyl or C_{1-6}alkyloxy(hydroxy)C_{1-6}alkyl; R^{17} and R^{18} are each independently selected from hydrogen, C_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, arylC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl or hydroxyC_{1-6}alkyl;
$—Q^{\cdots\cdots}Y<$ is $-CR^9=C<$ and then the dotted line is a bond,

-CHR^9-CH< or -CHR^9-N<; R^1 is hydrogen, heteroaryl, C_{1-6}alkyloxycarbonyl, C_{1-12}alkyl or C_{1-12}alkyl substituted with heteroaryl; R^2 is hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyloxy or phenylthio; R^3 is hydrogen, C_{1-6}alkyl or heteroaryl; R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, hydroxy or C_{1-6}alkyloxy; when p is 1 then R^7 is arylC_{1-6}alkyl or hydroxy; Z is a radical selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-8), (a-9), (a-10) and (a-11); each R^{10} or R^{11} are each independently selected from hydrogen, halo, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkylcarbonyl, C_{3-7}cycloalkyl(hydroxy)C_{1-6}alkyl, arylC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{2-6}alkenyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and -$(CH_2)_v$-$(C(=O)_r)$-$(CHR^{19})_u$-$NR^{13}R^{14}$; v is 0 or 1; u is 0 or 1; R^{12} is hydrogen or C_{1-6}alkyl; R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, arylC_{1-6}alkylcarbonyl, C_{3-7}cycloalkylcarbonyl, -$(CH_2)_k$-$NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C_{1-6}alkyloxycarbonyl or aryl; R^{13} and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, pyrrolidinyl, piperazinyl or piperazinyl substituted with a substituent selected from C_{1-6}alkyl or arylC_{1-6}alkyloxycarbonyl; k is 2; R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl or arylC_{1-6}alkyloxycarbonyl; k is 2; R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl or arylC_{1-6}alkyloxycarbonyl; R^{15} and R^{16} together with the nitrogen to which they are attached can optionally form a morpholinyl or piperazinyl, or a piperazinyl substituted with C_{1-6}alkyloxycarbonyl; aryl is phenyl or phenyl substituted with halo; heteroaryl is pyridinyl, indolyl, oxadiazolyl or tetrazolyl; and each pyridinyl, indolyl, oxadiazolyl or tetrazolyl can optionally be substituted with one substituent selected from C_{1-6}alkyl, aryl or arylC_{1-6}alkyl.

5. A compound according to any one of the preceding claims wherein m is 0; n is 1; p is 0; s is 0; t is 0.

6. A compound according to any one of the preceding claims wherein X is CHR^8 with R^8 is hydrogen.

7. A compound according to any one of the preceding claims wherein $—Q^{\cdots\cdots}Y<$ is $-CR^9=C<$ with R^9 is hydrogen.

8. A compound according to any one of the preceding claims wherein R^1 is hydrogen; R^3 is hydrogen; R^6 is hydrogen.

9. A compound according to any one of the preceding claims wherein R^4 and R^5 are each independently hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxy.



10. A compound according to any one of the preceding claims wherein Z is a radical selected from (a-1), (a-2), (a-3) or (a-4).










11. A compound according to any one of the preceding claims wherein R^{10} or R^{11} are each independently selected from hydrogen, hydroxy or hydroxyC_{1-6}alkyl.

12. A compound according to any one of the preceding claims wherein R^2 is hydrogen or C_{1-6}alkyloxy.

13. A compound according to any one of the preceding claims wherein m is 0; n is 1; p is 0; s is 0; t is 0; X is CHR^8; R^8 is hydrogen; $—Q^{\cdots\cdots}Y<$ is $-CR^9=C<$; each R^9 is hydrogen; R^1 is hydrogen; R^2 is hydrogen or C_{1-6}alkyloxy; R^3 is hydrogen; R^4 and R^5 are each independently hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxy; R^6 is hydrogen; Z is a radical selected from (a-1), (a-2), (a-3) or (a-4); and R^{10} or R^{11} are each independently selected from hydrogen, hydroxy or hydroxyC_{1-6}alkyl.


14. A compound according to claim 1, 2, 3 or 4 wherein the compound is selected from the following compounds

	
1.58 HCl	

	
	
	
	
	(B)
	


a *N*-oxide form, an addition salt or a stereochemically isomeric form thereof.

15. A compound according to any one of the preceding claims wherein the compound is




a *N*-oxide form or an addition salt thereof.

16. A compound according to claim 15 wherein the compound is



or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 16 wherein the compound is



18. A compound according to any one of claims 1 to 17 for use as a medicine.

19. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 17.

20. Use of a compound according to any one of claims 1 to 17 for the manufacture of a medicament for treating cancer.

21. Use according to claim 20 wherein the cancer is selected from lung cancer (e.g. adenocarcinoma and including non-small cell lung cancer), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), oesophageal cancer, oral squamous carcinoma, tongue carcinoma, gastric carcinoma, nasopharyngeal cancer, hematopoietic tumours of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumours of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, brain tumors, gliomas, benign tumour of the skin (e.g. keratoacanthomas), breast carcinoma (e.g. advanced breast cancer), kidney carcinoma, ovary carcinoma, cervical carcinoma, endometrial carcinoma, bladder carcinoma, prostate cancer including the advanced disease, testicular cancers, osteosarcoma, head and neck cancer and epidermal carcinoma.

22. Use according to claim 21 wherein the cancer is selected from lung cancer including adenocarcinoma and including non-small cell lung cancer, breast carcinoma, colon cancer e.g. colorectal carcinomas, acute myelogenous leukaemia, ovary carcinoma, bladder carcinoma, hematopoietic tumor of lymphoid lineage.

23. Use according to claim 22 wherein the cancer is breast carcinoma.

24. Use according to claim 22 wherein the cancer is a hematopoietic tumor of lymphoid lineage.

25. Use according to claim 20 wherein the treatment involves sensitising tumour cells for chemotherapy or radiotherapy.


26. A combination of an anti-cancer agent and a compound according to any one of claims 1 to 17.

27. A combination according to claim 26 wherein the anti-cancer agent is selected from platinum coordination compounds for example cisplatin, carboplatin or oxalyplatin; taxane compounds for example paclitaxel or docetaxel; topoisomerase I inhibitors such as camptothecin compounds for example irinotecan or topotecan; topoisomerase II inhibitors such as anti-tumour podophyllotoxin derivatives for example etoposide or teniposide; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; alkylating agents such as nitrogen mustard or nitrosourea for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin, idarubicin or mitoxantrone; HER2 antibodies for example trastuzumab; estrogen receptor antagonists or selective estrogen receptor modulators for example tamoxifen, toremifene, droloxifene, faslodex or raloxifene; aromatase inhibitors such as exemestane, anastrozole, letrazole and vorozole; differentiating agents such as retinoids, vitamin D and retinoic acid metabolism blocking agents (RAMBA) for example accutane; DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavoperidol, imatinib mesylate or gefitinib; farnesyltransferase inhibitors; HDAC inhibitors; inhibitors of the ubiquitin-proteasome pathway for example Velcade; or Yondelis.

28. A product containing as first active ingredient a compound according to any one of claims 1 to 17 and as second active ingredient an anticancer agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.


29. A process for preparing a compound as claimed in claim 1, characterized by

a) reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W is an appropriate leaving group such as, for example, halo,




wherein the variables are as defined in claim 1;

b) converting a compound of formula (I) wherein X is C(=O), herein referred to as compounds of formula (I-b), into compounds of formula (I), wherein X is CH_2, herein referred to as compounds of formula (I-a), in the presence of lithium aluminium hydride in a suitable solvent,




(I-b)




(I-a)

wherein the variables are as defined in claim 1;

c) reacting an appropriate carboxaldehyde of formula (IV), with an intermediate of formula (V), in the presence of an appropriate reagent, in a suitable solvent,




(IV) (V)



(I-a)

wherein the variables are as defined in claim 1;


d) reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula (VI) with the formation of a compound of formula (I), wherein t is 1, herein referred to as compounds of formula (I-c),



(II) (VI) (I-c)

wherein the variables are as defined in claim 1;

e) reacting an intermediate of formula (VII) with lithium aluminium hydride in a suitable solvent, with the formation of a compound of formula (I), wherein s is 1, herein referred to as compounds of formula (I-d).




(VII) (I-d)

wherein the variables are as defined in claim 1.

CLAIMS

1. A compound of formula (I),



(I)

a *N*-oxide form, an addition salt or a stereochemically isomeric form thereof, wherein

m is 0, 1, or 2 and when m is 0 then a direct bond is intended;

n is 0, 1, 2, or 3 and when n is 0 then a direct bond is intended;

p is 0, or 1 and when p is 0 then a direct bond is intended;

s is 0, or 1 and when s is 0 then a direct bond is intended;

t is 0 or 1 and when t is 0 then a direct bond is intended;

X is C(=O) or CHR^8; wherein

R^8 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, -C(=O)-$NR^{17}R^{18}$, hydroxycarbonyl, arylC_{1-6}alkyloxycarbonyl, heteroaryl, heteroarylcarbonyl, heteroarylC_{1-6}alkyloxycarbonyl, piperazinylcarbonyl, pyrrolidinyl, piperidinylcarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; piperazinylcarbonyl substituted with hydroxy, hydroxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl; pyrrolidinyl substituted with hydroxyC_{1-6}alkyl; or piperidinylcarbonyl substituted with one or two substituents selected from hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyl(dihydroxy)C_{1-6}alkyl or C_{1-6}alkyloxy(hydroxy)C_{1-6}alkyl;

R^{17} and R^{18} are each independently selected from hydrogen, C_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, arylC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyl,

hydroxyC_{1-6}alkyl(C_{1-6}alkyl) or hydroxyC_{1-6}alkyl(arylC_{1-6}alkyl);

—Q⋯⋯Y< is -CR^9=C< and then the dotted line is a bond, -CHR^9-CH< or -CHR^9-N<;

wherein

each R^9 is independently hydrogen or C_{1-6}alkyl;

R^1 is hydrogen, aryl, heteroaryl, C_{1-6}alkyloxycarbonyl, C_{1-12}alkyl, or C_{1-12}alkyl substituted with one or two substituents independently selected from hydroxy, aryl, heteroaryl, amino, C_{1-6}alkyloxy, mono- or di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C_{1-6}alkylpiperazinyl, arylC_{1-6}alkylpiperazinyl, heteroarylC_{1-6}alkylpiperazinyl, C_{3-7}cycloalkylpiperazinyl and C_{3-7}cycloalkylC_{1-6}alkylpiperazinyl;

R^2 is hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyloxy, heteroarylC_{1-6}alkyloxy, phenylthio, hydroxyC_{1-6}alkylcarbonyl, C_{1-6}alkyl substituted with a substituent selected from amino, aryl and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from amino, aryl and heteroaryl;

R^3 is hydrogen, C_{1-6}alkyl, heteroaryl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl;


R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, hydroxy, amino or C_{1-6}alkyloxy; or

R^4 and R^5 together can optionally form a bivalent radical selected from methylenedioxy or ethylenedioxy;


R^6 is hydrogen, C_{1-6}alkyloxycarbonyl or C_{1-6}alkyl;

when p is 1 then R^7 is hydrogen, arylC_{1-6}alkyl, hydroxy or heteroarylC_{1-6}alkyl;


Z is a radical selected from




(a-1)




(a-2)





(a-3)





(a-4)



(a-5)



(a-6)


(a-7)


(a-8)


(a-9)


(a-10)


(a-11)

wherein

each R^{10} or R^{11} are each independently selected from hydrogen, halo, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, heteroaryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, heteroarylcarbonyl, C_{1-6}alkylcarbonyl, arylC_{1-6}alkylcarbonyl, heteroarylC_{1-6}alkylcarbonyl, C_{1-6}alkyloxy, C_{3-7}cycloalkylcarbonyl, C_{3-7}cycloalkyl(hydroxy)C_{1-6}alkyl, arylC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{2-6}alkenyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and $-(CH_2)_v-(C(=O)_r)-(CHR^{19})_u-NR^{13}R^{14}$; wherein

v is 0, 1, 2, 3, 4, 5, or 6 and when v is 0 then a direct bond is intended;

r is 0, or 1 and when r is 0 then a direct bond is intended;

u is 0, 1, 2, 3, 4, 5, or 6 and when u is 0 then a direct bond is intended;

R^{19} is hydrogen or C_{1-6}alkyl;

R^{12} is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, C_{1-6}alkyloxy and aryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and C_{1-6}alkyloxy;

R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl,

C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, arylC_{1-6}alkylcarbonyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylcarbonyl, $-(CH_2)_k-NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyloxy, aryl or heteroaryl; or

C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, amino, arylC_{1-6}alkyl, heteroaryl or heteroarylC_{1-6}alkyl; or

R^{13} and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, or piperazinyl substituted with a substituent selected from C_{1-6}alkyl, arylC_{1-6}alkyl, arylC_{1-6}alkyloxycarbonyl, heteroarylC_{1-6}alkyl, C_{3-7}cycloalkyl and C_{3-7}cycloalkylC_{1-6}alkyl; wherein

k is 0, 1, 2, 3, 4, 5, or 6 and when k is 0 then a direct bond is intended;

R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl, arylC_{1-6}alkyloxycarbonyl, C_{3-7}cycloalkyl, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; and C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl, and heteroarylC_{1-6}alkyl; or

R^{15} and R^{16} together with the nitrogen to which they are attached can optionally form a morpholinyl, a piperazinyl or a piperazinyl substituted with C_{1-6}alkyloxycarbonyl;

aryl is phenyl or naphthalenyl;

each phenyl or naphthalenyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl and C_{1-6}alkyloxy; and

each phenyl or naphthalenyl can optionally be substituted with a bivalent radical selected from methylenedioxy and ethylenedioxy;

heteroaryl is pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl or tetrahydrofuranyl;

each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, oxadiazolyl, tetrazolyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl, aryl, arylC_{1-6}alkyl or C_{1-6}alkyloxy; and

each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from methylenedioxy or ethylenedioxy;

with the proviso that
when m is 1; the substituents on the phenyl ring other than R^2 are in the meta position; s is 0; and t is 0; then
Z is a radical selected from (a-1), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8) or (a-9).

2. A compound according to claim 1 wherein X is C(=O) or CHR^8 wherein R^8 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, aminocarbonyl, mono- or di(C_{1-6}alkyl)aminocarbonyl, hydroxycarbonyl, arylC_{1-6}alkyloxycarbonyl, heteroarylC_{1-6}alkyloxycarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; R^1 is hydrogen, aryl, heteroaryl, C_{1-12}alkyl, or C_{1-12}alkyl substituted with one or two substituents independently selected from hydroxy, aryl, heteroaryl, amino, C_{1-6}alkyloxy, mono- or di(C_{1-6}alkyl)amino, morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, C_{1-6}alkylpiperazinyl, arylC_{1-6}alkylpiperazinyl,heteroarylC_{1-6}alkylpiperazinyl, C_{3-7}cycloalkylpiperazinyl and C_{3-7}cycloalkylC_{1-6}alkylpiperazinyl; R^3 is hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-6}alkyl substituted with a substituent selected from hydroxy, amino, aryl, and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, polyhaloC_{1-6}alkyl, hydroxy, amino or C_{1-6}alkyloxy; R^4 and R^5 together can optionally form a bivalent radical selected from methylenedioxy or ethylenedioxy; R^6 is hydrogen or C_{1-6}alkyl; when p is 1 then R^7 is hydrogen, arylC_{1-6}alkyl or heteroarylC_{1-6}alkyl; Z is a radical selected from (a-1), (a-2), (a-3), (a-4), (a-5) and (a-6); each R^{10} or R^{11} are each independently selected from hydrogen, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, heteroaryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, heteroarylcarbonyl, arylC_{1-6}alkylcarbonyl, heteroarylC_{1-6}alkylcarbonyl, C_{1-6}alkyloxy, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyloxy, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and $-(CH_2)_v-(C(=O)_r)-(CH_2)_u-NR^{13}R^{14}$; R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl, C_{3-7}cycloalkyl, $-(CH_2)_k-NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; or C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl and heteroarylC_{1-6}alkyl; R^{13}


and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, or piperazinyl substituted with a substituent selected from C_{1-6}alkyl, arylC_{1-6}alkyl, heteroarylC_{1-6}alkyl, C_{3-7}cycloalkyl, and C_{3-7}cycloalkylC_{1-6}alkyl; R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl, C_{3-7}cycloalkyl, C_{1-12}alkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, and heteroaryl; and C_{3-7}cycloalkyl substituted with a substituent selected from hydroxy, C_{1-6}alkyloxy, aryl, arylC_{1-6}alkyl, heteroaryl and heteroarylC_{1-6}alkyl; heteroaryl is pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl; and each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with one, two or three substituents each independently selected from halo, hydroxy, C_{1-6}alkyl, amino, polyhaloC_{1-6}alkyl and C_{1-6}alkyloxy, or each pyridinyl, indolyl, quinolinyl, imidazolyl, furanyl, thienyl, benzofuranyl, or tetrahydrofuranyl can optionally be substituted with a bivalent radical selected from methylenedioxy or ethylenedioxy.

3. A compound according to claim 1 wherein;
R^8 is hydrogen, -C(=O)-$NR^{17}R^{18}$, arylC_{1-6}alkyloxycarbonyl, C_{1-6}alkyl substituted with hydroxy, piperazinylcarbonyl substituted with hydroxy, hydroxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, pyrrolidinyl substituted with hydroxyC_{1-6}alkyl or piperidinylcarbonyl substituted with one or two substituents selected from hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyl(dihydroxy)C_{1-6}alkyl or C_{1-6}alkyloxy(hydroxy)C_{1-6}alkyl; R^{17} and R^{18} are each independently selected from hydrogen, C_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, arylC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl or hydroxyC_{1-6}alkyl;
—Q=Y< is -CR^9=C< and then the dotted line is a bond, -CHR^9-CH< or -CHR^9-N<; R^1 is hydrogen, heteroaryl, C_{1-6}alkyloxycarbonyl, C_{1-12}alkyl or C_{1-12}alkyl substituted with heteroaryl; R^2 is hydrogen, halo, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyloxy or phenylthio; R^3 is hydrogen, C_{1-6}alkyl or heteroaryl; R^4 and R^5 are each independently hydrogen, halo, C_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, hydroxy or C_{1-6}alkyloxy; when p is 1 then R^7 is arylC_{1-6}alkyl or hydroxy; Z is a radical selected from (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), (a-8), (a-9), (a-10) and (a-11); each R^{10} or R^{11} are each independently selected from hydrogen, halo, hydroxy, amino, C_{1-6}alkyl, nitro, polyhaloC_{1-6}alkyl, cyano, cyanoC_{1-6}alkyl, tetrazoloC_{1-6}alkyl, aryl, heteroaryl, heteroarylC_{1-6}alkyl, aryl(hydroxy)C_{1-6}alkyl, arylcarbonyl, C_{1-6}alkylcarbonyl, C_{3-7}cycloalkylcarbonyl, C_{3-7}cycloalkyl(hydroxy)C_{1-6}alkyl, arylC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkylcarbonyloxyC_{1-6}alkyl,

C_{1-6}alkyloxycarbonylC_{1-6}alkyloxyC_{1-6}alkyl, hydroxyC_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonylC_{2-6}alkenyl, C_{1-6}alkyloxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, aminocarbonyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl, hydroxycarbonyl, hydroxycarbonylC_{1-6}alkyl and $-(CH_2)_v-(C(=O)_r)-(CHR^{19})_u-NR^{13}R^{14}$; v is 0 or 1; u is 0 or 1; R^{12} is hydrogen or C_{1-6}alkyl; R^{13} and R^{14} are each independently selected from hydrogen, C_{1-12}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkylsulfonyl, arylC_{1-6}alkylcarbonyl, C_{3-7}cycloalkylcarbonyl, $-(CH_2)_k-NR^{15}R^{16}$, C_{1-12}alkyl substituted with a substituent selected from hydroxy, hydroxycarbonyl, cyano, C_{1-6}alkyloxycarbonyl or aryl; R^{13} and R^{14} together with the nitrogen to which they are attached can optionally form a morpholinyl, pyrrolidinyl, piperazinyl or piperazinyl substituted with a substituent selected from C_{1-6}alkyl or arylC_{1-6}alkyloxycarbonyl; k is 2; R^{15} and R^{16} are each independently selected from hydrogen, C_{1-6}alkyl or arylC_{1-6}alkyloxycarbonyl;
R^{15} and R^{16} together with the nitrogen to which they are attached can optionally form a morpholinyl or piperazinyl, or a piperazinyl substituted with C_{1-6}alkyloxycarbonyl; aryl is phenyl or phenyl substituted with halo; heteroaryl is pyridinyl, indolyl, oxadiazolyl or tetrazolyl; and each pyridinyl, indolyl, oxadiazolyl or tetrazolyl can optionally be substituted with one substituent selected from C_{1-6}alkyl, aryl or arylC_{1-6}alkyl.

4. A compound according to any one of the preceding claims wherein m is 0; n is 1; p is 0; s is 0; t is 0.

5. A compound according to any one of the preceding claims wherein X is CHR^8 with R^8 is hydrogen.

6. A compound according to any one of the preceding claims wherein  is $-CR^9=C<$ with R^9 is hydrogen.

7. A compound according to any one of the preceding claims wherein R^1 is hydrogen; R^3 is hydrogen; R^6 is hydrogen.

8. A compound according to any one of the preceding claims wherein R^4 and R^5 are each independently hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxy.









9. A compound according to any one of the preceding claims wherein Z is a radical selected from (a-1), (a-2), (a-3) or (a-4).




10. A compound according to any one of the preceding claims wherein R^{10} or R^{11} are each independently selected from hydrogen, hydroxy or hydroxyC_{1-6}alkyl.

11. A compound according to any one of the preceding claims wherein R^2 is hydrogen or C_{1-6}alkyloxy.

12. A compound according to any one of the preceding claims wherein m is 0; n is 1; p is 0; s is 0; t is 0; X is CHR^8; R^8 is hydrogen; —Q=Y< is $-CR^9=C<$; each R^9 is hydrogen; R^1 is hydrogen; R^2 is hydrogen or C_{1-6}alkyloxy; R^3 is hydrogen; R^4 and R^5 are each independently hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxy; R^6 is hydrogen; Z is a radical selected from (a-1), (a-2), (a-3) or (a-4); and R^{10} or R^{11} are each independently selected from hydrogen, hydroxy or hydroxyC_{1-6}alkyl.


13. A compound according to claim 1, 2 or 3 wherein the compound is selected from Co. No. 1, Co. No. 21, Co. No. 4, Co. No. 5, Co. No. 36, No. 69, Co. No. 110, Co. No. 111, Co. No. 112, Co. No. 229 and Co. No. 37

	
Co. No. 1; .1.58 HCl	Co. No. 21
	
Co. No. 4	Co. No. 5
	
Co. No. 36	Co. No. 69
	
Co. No. 110	Co. No. 111

	
Co. No. 112	Co. No. 229; (B)
	
Co. No. 37	


a *N*-oxide form, an addition salt or a stereochemically isomeric form thereof.

14. A compound according to any one of the preceding claims wherein the compound is



or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 14 wherein the compound is



16. A compound according to any one of claims 1 to 15 for use as a medicine.

17. A compound according to any one of claims 1 to 15 for treating cancer.

18. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 15.

19. Use of a compound according to any one of claims 1 to 15 for the manufacture of a medicament for treating cancer.

20. Use according to claim 19 wherein the cancer is selected from lung cancer (e.g. adenocarcinoma and including non-small cell lung cancer), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), oesophageal cancer, oral squamous carcinoma, tongue carcinoma, gastric carcinoma, nasopharyngeal cancer, hematopoietic tumours of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumours of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, brain tumors, gliomas, benign tumour of the skin (e.g. keratoacanthomas), breast carcinoma (e.g. advanced breast cancer), kidney carcinoma, ovary carcinoma, cervical carcinoma, endometrial carcinoma, bladder carcinoma, prostate cancer including the advanced disease, testicular cancers, osteosarcoma, head and neck cancer and epidermal carcinoma.

21. Use according to claim 20 wherein the cancer is selected from non-small cell lung cancer, breast carcinoma, colon cancer e.g. colorectal carcinomas, acute myelogenous leukaemia, ovary carcinoma, bladder carcinoma, prostate cancer, glioma.


22. A combination of an anti-cancer agent and a compound according to any one of claims 1 to 15.

23. A combination according to claim 22 wherein the anti-cancer agent is selected from platinum coordination compounds for example cisplatin, carboplatin or oxalyplatin; taxane compounds for example paclitaxel or docetaxel; topoisomerase I inhibitors such as camptothecin compounds for example irinotecan or topotecan; topoisomerase II inhibitors such as anti-tumour podophyllotoxin derivatives for example etoposide or teniposide; anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine; anti-tumour nucleoside derivatives for example 5-fluorouracil, gemcitabine or capecitabine; alkylating agents such as nitrogen mustard or nitrosourea for example cyclophosphamide, chlorambucil, carmustine or lomustine; anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin, idarubicin or mitoxantrone; HER2 antibodies for example trastuzumab; estrogen receptor antagonists or selective estrogen receptor modulators for example tamoxifen, toremifene, droloxifene, faslodex or raloxifene;

aromatase inhibitors such as exemestane, anastrozole, letrazole and vorozole; differentiating agents such as retinoids, vitamin D and retinoic acid metabolism blocking agents (RAMBA) for example accutane; DNA methyl transferase inhibitors for example azacytidine; kinase inhibitors for example flavopiridol, imatinib mesylate or gefitinib; farnesyltransferase inhibitors; HDAC inhibitors; inhibitors of the ubiquitin-proteasome pathway for example Velcade; or Yondelis.


24. A product containing as first active ingredient a compound according to any one of claims 1 to 15 and as second active ingredient an anticancer agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of patients suffering from cancer.

25. A process for preparing a compound as claimed in claim 1, characterized by
a) reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W is an appropriate leaving group such as, for example, halo,




wherein the variables are as defined in claim 1;

b) converting a compound of formula (I) wherein X is C(=O), herein referred to as compounds of formula (I-b), into compounds of formula (I), wherein X is CH_2, herein referred to as compounds of formula (I-a), in the presence of lithium aluminium hydride in a suitable solvent,




(I-b)




(I-a)

wherein the variables are as defined in claim 1;

c) reacting an appropriate carboxaldehyde of formula (IV), with an intermediate of formula (V), in the presence of an appropriate reagent, in a suitable solvent,




(IV) (V)



(I-a)


wherein the variables are as defined in claim 1;

d) reacting an intermediate of formula (II) with an appropriate carboxaldehyde of formula (VI) with the formation of a compound of formula (I), wherein t is 1, herein referred to as compounds of formula (I-c),



wherein the variables are as defined in claim 1;

e) reacting an intermediate of formula (VII) with lithium aluminium hydride in a suitable solvent, with the formation of a compound of formula (I), wherein s is 1, herein referred to as compounds of formula (I-d).



wherein the variables are as defined in claim 1.